Servier ready to launch its colorectal cancer drug in Russia

7 July 2020

French independent pharma major Servier plans to launch its Lonsurf (tipiracil and trifluridine) drug in the Russian market shortly, according to the company.The drug is recommended for the treatment of cancers, including colorectal cancer and, as part of the company’s plans, may enjoy a significant demand among the local patients.

So far, the drug has been approved in three states of the Eurasian Economic Union (Armenia, Belarus, Kyrgyzstan) and it is expected that the decision to approve Lonsurf may soon be taken with regard to Russia.

According to Natalya Chukreeva, Servier’s director of pharmaceutical activities for the EAEU countries, the company has high hopes for its drug in the Russian market.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK